Evidence map›Paper›PMID 32726923›Full record

ReviewInternational journal of molecular sciences2020

Biomarkers in Colorectal Cancer: Current Research and Future Prospects.

Olorunseun O Ogunwobi, Fahad Mahmood, Akinfemi Akingboye

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 7 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 7 syntheses or guidelines pooled it, 257 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. The emerging metabolic role and treatment target of CPT1A in CRC.Frontiers in cell and developmental biology · 2026
    Review
  17. Article
  18. Article
  19. A new combined prognostic model involvingTranslational cancer research · 2025
    Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Olorunseun O OgunwobiDepartment of Biological Sciences, Hunter College of The City University of New York, New York, NY 10065, USA.ORCID 0000-0003-3388-2137
Fahad MahmoodThe Dudley Group Hospitals, Russells Hall Hospital, The Dudley Group NHS Foundation Trust, Dudley, West Midlands DY1 2HQ, UK.ORCID 0000-0003-1776-8828
Akinfemi AkingboyeThe Dudley Group Hospitals, Russells Hall Hospital, The Dudley Group NHS Foundation Trust, Dudley, West Midlands DY1 2HQ, UK.
Russells Hall Hospital · GBCity University of New York · US

Funding

TUFCCC/HC Regional Comprehensive Cancer Health PartnershipU54CA221704 · NCI · HUNTER COLLEGE · PI Ming-Chin Yeh · 2018 to 2026
$10.6M
NCI NIH HHS U54 CA221704NCI NIH HHS U54CA221704
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in detection and management through surgery, chemotherapy, radiotherapy, and immunotherapy. Novel therapeutic agents have improved survival in both the adjuvant and advanced disease settings, albeit with an increased risk of toxicity and cost. However, metastatic disease continues to have a poor long-term prognosis and significant challenges remain due to late stage diagnosis and treatment failure. Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response. The past three decades have seen advances in genomics and molecular pathology of cancer biomarkers, allowing for greater individualization of therapy with a positive impact on survival outcomes. Clinically useful predictive biomarkers aid clinical decision making, such as the presence of

Indexed as

Biomarkers, TumorColorectal NeoplasmsProto-Oncogene Proteins p21(ras)RNA, Long NoncodingRNA, NeoplasmErbB ReceptorsHumansPrognosisBiomarkers, TumorEGFR protein, humanErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins p21(ras)PVT1 long-non-coding RNA, humanRNA, Long NoncodingRNA, Neoplasmbiomarkercolorectal cancerdiagnosisprognosticationPVT1screening

Identifiers

PMID32726923
PMCPMC7432436
OpenAlexW3045398807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.